Blood News and Research

RSS

Feinstein Institute scientists seek sisters for lupus study

The SisSLE (Sisters of Women with Systemic Lupus Erythematosus) research study is looking for sisters: one with a diagnosis of systemic lupus erythematosus (SLE), an autoimmune disease and one (or more) who does not have lupus.

31 Mar 2010

Plant-based system could help improve lives of hemophilic patients

Hemophilia, a disease linked with legends of European monarchs, frail heirs and one flamboyant charlatan called Rasputin, still afflicts many people today.

31 Mar 2010

Optometrists and dietitians are important part of health care team

For people with diabetes, proper nutrition can have a far-reaching effect on their health and wellness. They also have a higher risk of developing vision problems. March is National Nutrition Month and Save Your Vision Month, and the American Dietetic Association (ADA) and American Optometric Association (AOA) would like to remind people that optometrists and registered dietitians are an important part of the health care team.

31 Mar 2010

BIO pleased with Court's dismissal of claims over patenting gene-based inventions

“As explained in the ruling yesterday, the District Court's determination is only a preliminary step in the legal process that does not affect how the U.S. Patent and Trademark Office (PTO) evaluates patent applications relating to DNA-based inventions.”

31 Mar 2010

HHMI awards 2010 Gilliam Fellowship to UT Southwestern student

Mariam El-Ashmawy, a student enrolled in UT Southwestern Medical Center's prestigious Medical Scientist Training Program, has been awarded a 2010 Gilliam Fellowship for Advanced Study from the Howard Hughes Medical Institute (HHMI).

31 Mar 2010

$Notch pathway could aid treatment of osteoporosis, fractures and arthritis$

Notch pathway could aid treatment of osteoporosis, fractures and arthritis

Scientists seeking new ways to fight maladies ranging from arthritis and osteoporosis to broken bones that won't heal have cleared a formidable hurdle, pinpointing and controlling a key molecular player to keep stem cells in a sort of extended infancy.

31 Mar 2010

New anti-inflammatory drug shows promise for treating inflammatory disorders

Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs) remain the most common treatment to relieve symptoms of arthritis and other inflammatory disorders. But despite their widespread use (around 2.5 million Canadians have osteoarthritis) these medications are also known to cause severe, sometimes life-threatening adverse effects within the body, particularly in the gastrointestinal tract

31 Mar 2010

Drinking orange juice with fast-food meal may help prevent vascular inflammation

Eating foods containing flavonoids -- orange juice, in this case -- along with a high-fat, high-carbohydrate fast-food meal neutralizes the oxidative and inflammatory stress generated by the unhealthy food and helps prevent blood vessel damage, a new study by University at Buffalo endocrinologists shows.

31 Mar 2010

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.

31 Mar 2010

AgaMatrix, sanofi-aventis announce long-term partnership for BGM solutions

AgaMatrix, Inc. and sanofi-aventis today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes management that incorporate AgaMatrix's WaveSense™ technology. Sanofi-aventis will commercialize through its Global Diabetes Division such integrated solutions for patients with diabetes, along with current sanofi-aventis insulins and delivery devices.

31 Mar 2010

Roche Diagnostics' CoaguChek XS Plus system granted CLIA-waived status

Roche Diagnostics announced today that the U.S. Food and Drug Administration (FDA) has granted CLIA-waived status to the CoaguChek® XS Plus system, a point-of-care anticoagulation monitor that offers connectivity and data management tools to help healthcare professionals manage PT/INR (blood clotting time) testing.

From Roche Sequencing and Life Science 31 Mar 2010

Eisai seeks simultaneous approval of eribulin mesylate in U.S., EU and Japan

Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the United States and the European Union (EU). Eribulin, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai.

31 Mar 2010

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

New drugs that are helping fight a multi-front war on cancer may do the same for cardiovascular disease, Medical College of Georgia researchers said.

31 Mar 2010

Reverse Medical closes Series-B private equity financing

Reverse Medical Corporation announced today the closing of their Series-B private equity financing. The Company raised $14 million from new investors Wexford Capital, Getz Bros., BioStar Ventures, Early Stage Partners and Emergent Medical Partners.

31 Mar 2010

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma announced today initiation of the Company's first Phase 1 trial to evaluate the pharmacokinetic (PK) profiles of experimental controlled-release (CR) morphine and oxycodone formulations that will be incorporated into MoxDuo®CR. MoxDuo®CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain, an approximately US$7 billion dollar market worldwide.

31 Mar 2010

Asclera injection receives FDA approval

The U.S. Food and Drug Administration today approved Asclera (polidocanol) injection for the treatment of small types of abnormally swollen or twisted veins called varicose veins.

31 Mar 2010

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).

31 Mar 2010

Ikaria Holdings acquires NDA and IND application for LUCASSIN drug

Ikaria Holdings, Inc. announced today that it has acquired the New Drug Application (NDA) and the Investigational New Drug (IND) application to LUCASSIN® (terlipressin for injection) from Orphan Therapeutics, assuming all future development and ownership of the drug in North America and Australia.

31 Mar 2010

National Donate Life Month: Facts surrounding dire need for organ donations

With Thursday, April 1, 2010, marking the start of "National Donate Life Month," Health Net, Inc. is working to increase awareness regarding the urgent need for organ donations - particularly among minority populations - and also to dispute some of the misperceptions surrounding organ donation.

30 Mar 2010